NCT00169572.

Methods	Randomised, phase 2, parallel‐assignment study Study start date: February 2005 Study completion date: not provided number of enrolled subjects: 492 Masking: double‐blind Baseline patient characteristics: n.r.
Participants	Inclusion criteria willing to provide written informed consent before receiving any study‐specific procedures or assessments diagnosed solid malignant tumour has not previously received chemotherapy scheduled to receive chemotherapy conducive to regimens outlined in the study protocol Exclusion criteria has not received any investigational product within 30 days of enrolment into the study must not be pregnant must not be of child‐bearing potential or willing to use specific barrier methods outlined in the protocol must not be scheduled to receive radiation therapy to abdomen or pelvis within seven (7) days before the start of study medication must not be currently under treatment for a condition that may cause nausea or vomiting (e.g. active peptic ulcer disease, gastric obstruction) must not have a history of peptic ulcer disease Mean/median age, years: n.r. Gender: male + female Tumour/cancer type: solid malignancy Chemotherapy regimen: n.r. Country: Argentina, Austria, Belgium, Chile, Croatia, Czech Republic, Hong Kong, Hungary, Italy, Mexico, Netherlands, Pakistan, Peru, Philippines, Poland, Romania, Singapore, Slovakia, Taiwan
Interventions	Drug: aprepitant, ondansetron, GW679769, dexamethasone Study arms: not provided
Outcomes	Primary outcome number of subjects who do not experience vomiting, retching, or nausea over a 5‐day period following initiation of chemotherapy Secondary outcomes routine physical exam findings, vital signs, routine clinical laboratory tests, clinical monitoring and/or observation, adverse events reporting
Notes	ClinicalTrials.gov identifier (NCT number): NCT00169572 sponsors and collaborators: GlaxoSmithKline